GeorgeJHannaMD

HIV/AIDS Medicine

Independent Biopharmaceutical Consultant with Expertise in Clinical Drug Development, Scientific and Medical Affairs, and Infectious Diseases

Join to view full profile

Dr. Hanna is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Hanna's full profile

Already have an account?

Office
1805 Stuart Rd W
Princeton, NJ 08540
Is this information wrong?

Education & Training

Massachusetts General HospitalFellowship, Infectious Disease, 1996 - 2000
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1992 - 1995
Baylor College of MedicineClass of 1992

Certifications & Licensure

NJ State Medical License 2009 - 2021
IL State Medical License 2005 - 2008
PA State Medical License 2001 - 2022
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Infectious Disease

Clinical Trials

Phase I/II Study of ABT-378/Ritonavir in Combination With Reverse Transcriptase Inhibitors in Antiretroviral Naive HIV-Infected Patients Start of enrollment: 1997 Nov 01Hanna, G.

Publications & Presentations

PubMed

Once-Daily Doravirine for Initial Treatment of Adults Living With HIV-1: An Integrated Safety Analysis.
Thompson, M.,Orkin, C.,Molina, J. M.,Sax, P.,Cahn, P.,Squires, K.,Xu, X.,Rodgers, A.,Kumar, S.,Teppler, H.,Martin, E.,Hanna, G.,Hwang, C.> ;Clin. Infect. Dis.. 2019 May 24
Once-Daily Doravirine in HIV-1-Infected, Antiretroviral-Naive Adults: An Integrated Efficacy Analysis.
Orkin, C.,Molina, J. M.,Lombaard, J.,DeJesus, E.,Rodgers, A.,Kumar, S.,Martin, E.,Hanna, G.,Hwang, C.> ;Clin. Infect. Dis.. 2019 May 24
Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial.
Johnson, M.,Kumar, P.,Molina, J. M.,Rizzardini, G.,Cahn, P.,Bickel, M.,Mallolas, J.,Zhou, Y.,Morais, C.,Kumar, S.,Sklar, P.,Hanna, G. J.,Hwang, C.,Greaves, W.> ;J. Acquir. Immune Defic. Syndr.. 2019 Apr 16
Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting.
Julg, B.,Dee, L.,Ananworanich, J.,Barouch, D. H.,Bar, K.,Caskey, M.,Colby, D. J.,Dawson, L.,Dong, K. L.,Dubé, K.,Eron, J.,Frater, J.,Gandhi, R. T.,Geleziunas, R.,Gould...> ;Lancet HIV. 2019 Mar 20
Efficacy and Safety of Ruzasvir 60 mg and Uprifosbuvir 450 mg for 12 Weeks in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 3, 4, or 6 Infection.
Lawitz, E.,Poordad, F.,Anderson, L. J.,Vesay, M.,Kelly, M. M.,Liu, H.,Gao, W.,Fernsler, D.,Asante-Appiah, E.,Robertson, M. N.,Hanna, G. J.,Barr, E.,Butterton, J.,Kowdl...> ;J. Viral Hepat.. 2019 Feb 11
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immun...
Orkin, C.,Squires, K. E.,Molina, J. M.,Sax, P. E.,Wong, W. W.,Sussmann, O.,Kaplan, R.,Lupinacci, L.,Rodgers, A.,Xu, X.,Lin, G.,Kumar, S.,Sklar, P.,Nguyen, B. Y.,Hanna,...> ;Clin. Infect. Dis.. 2018 Sep 06
Viral Drug Resistance through 48 Weeks, in a Phase 2b, Randomized, Controlled Trial of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir.
Lataillade, M.,Zhou, N.,Joshi, S. R.,Lee, S.,Stock, D. A.,Hanna, G. J.,Krystal, M.> ;J. Acquir. Immune Defic. Syndr.. 2017 Dec 06
Model-based Phase 3 dose selection for HIV-1 attachment inhibitor prodrug BMS-663068 in HIV-1-infected patients: population pharmacokinetics/pharmacodynamics of the ac...
Landry, I.,Zhu, L.,Abutarif, M.,Hruska, M.,Sadler, B. M.,Pitsiu, M.,Joshi, S.,Hanna, G. J.,Lataillade, M.,Boulton, D. W.,Bertz, R. J.> ;Antimicrob. Agents Chemother.. 2016 Feb 24
Efficacy, safety, bone and metabolic effects of HIV nucleoside reverse transcriptase inhibitor BMS-986001 (AI467003): a phase 2b randomised, controlled, partly blinded...
Gupta SK, McComsey GA, Lombaard J, Echevarria J, Orrell C, Avihingsanon A, Osiyemi O, Santoscoy M, Ray N, Stock DA, Joshi SR, Hanna GJ, Lataillade M> ;Lancet HIV. 2016 Jan
Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised cont...
Lalezari JP, Latiff GH, Brinson C, Echevarria J, Trevino-Perez S, Bogner JR, Thompson M, Fourie J, Sussmann Pena OA, Mendo Urbina FC, Martins M, Diaconescu IG, Stock D...> ;Lancet HIV. 2015 Oct
Enabled clinical use of an HIV-1 attachment inhibitor through drug delivery.
Timmins, P.,Brown, J.,Meanwell, N. A.,Hanna, G. J.,Zhu, L.,Kadow, J. F.> ;Drug Discov. Today. 2014 Apr 15
In vitro cross-resistance profile of nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 against known NRTI resistance mutations.
Li, Z.,Terry, B.,Olds, W.,Protack, T.,Deminie, C.,Minassian, B.,Nowicka-Sans, B.,Sun, Y.,Dicker, I.,Hwang, C.,Lataillade, M.,Hanna, G. J.,Krystal, M.> ;Antimicrob. Agents Chemother.. 2013 Aug 28
Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068.
Zhou, N.,Nowicka-Sans, B.,McAuliffe, B.,Ray, N.,Eggers, B.,Fang, H.,Fan, L.,Healy, M.,Langley, D. R.,Hwang, C.,Lataillade, M.,Hanna, G. J.,Krystal, M.> ;J. Antimicrob. Chemother.. 2013 Oct 17
Activity of the HIV-1 Attachment Inhibitor BMS-626529, the Active Component of the Prodrug BMS-663068, against CD4-Independent Viruses and HIV-1 Envelopes Resistant to...
Li, Z.,Zhou, N.,Sun, Y.,Ray, N.,Lataillade, M.,Hanna, G. J.,Krystal, M.> ;Antimicrob. Agents Chemother.. 2013 Sep
Randomized placebo-controlled study of the safety, tolerability, antiviral activity, and pharmacokinetics of 10-day monotherapy with BMS-986001, a novel HIV NRTI, in t...
Cotte, L.,Dellamonica, P.,Raffi, F.,Yazdanpanah, Y.,Molina, J. M.,Boué, F.,Urata, Y.,Chan, H. P.,Zhu, L.,Chang, I.,Bertz, R.,Hanna, G. J.,Grasela, D. M.,Hwang, C.> ;J. Acquir. Immune Defic. Syndr.. 2013 Jul 1
Prediction of virologic response and assessment of resistance emergence to the HIV-1 attachment inhibitor BMS-626529 during 8-day monotherapy with its prodrug BMS-663068.
Ray, N.,Hwang, C.,Healy, M. D.,Whitcomb, J.,Lataillade, M.,Wind-Rotolo, M.,Krystal, M.,Hanna, G. J.> ;J. Acquir. Immune Defic. Syndr.. 2013 Sep 1
Adherence to chronic hepatitis B treatment guideline recommendations for laboratory monitoring of patients who are not receiving antiviral treatment.
Juday, T., Tang, H., Harris, M., Powers, A.Z., Kim, E., Hanna, G.J.> ;J Gen Intern Med. 2011 Mar
In vivo patterns of resistance to the HIV attachment inhibitor BMS-488043.
Zhou, N., Nowicka-Sans, B., Zhang, S., Fan, L., Fang, J., Fang, H., Gong, Y., Eggers, B., Langley, D.R., Wang, T., Kadow, J., Grasela, D., Hanna, G.J., Alexander, L., ...> ;Antimicrob Agents Chemother. 2011 Feb
Antiviral activity, pharmacokinetics, and safety of BMS-488043, a novel oral small-molecule HIV-1 attachment inhibitor, in HIV-1-infected subjects.
Hanna, G.J., Lalezari, J., Hellinger, J.A., Wohl, D.A., Nettles, R., Persson, A., Krystal, M., Lin, P., Colonno, R., Grasela, D.M.> ;Antimicrob Agents Chemother. 2011 Feb
A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy.
Cameron, D.W., da Silva, B.A., Arribas, J.R., Myers, R.A., Bellos, N.C., Gilmore, N., King, M.S., Bernstein, B.M., Brun, S.C., Hanna, G.J.> ;J Infect Dis. 2008 Jul 15
"White coat compliance" limits the reliability of therapeutic drug monitoring in HIV-1-infected patients.
Podsadecki, T.J., Vrijens, B.C., Tousset, E.P., Rode, R.A., Hanna, G.J.> ;HIV Clin Trials. 2008-07-01
Effects of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and ritonavir-boosted atazanavir.
Klein, C.E., Chiu, Y., Cai, Y., Beck, K., King, K.R., Causemaker, S.J., Doan, T., Esslinger, H., Podsadecki, T.J., Hanna, G.J.> ;J Clin Pharmacol. 2008 May
Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy.
Palmer, S., Maldarelli, F., Wiegand, A., Bernstein, B., Hanna, G.J., Brun, S.C., Kempf, D.J., Mellors, J.W., Coffin, J.M., King, M.S.> ;Proc Natl Acad Sci U S A. 2008 Mar 11
Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naïve HIV-1-infected patients.
Murphy, R.L., da Silva, B.A., Hicks, C.B., Eron, J.J., Gulick, R.M., Thompson, M.A., McMillan, F., King, M.S., Hanna, G.J., Brun, S.C.> ;HIV Clin Trials. 2008-01-01
Decreased adherence to antiretroviral therapy observed prior to transient human immunodeficiency virus type 1 viremia.
Podsadecki, T.J., Vrijens, B.C., Tousset, E.P., Rode, R.A., Hanna, G.J.> ;J Infect Dis. 2007 Dec 15
Join now to see all

Press Mentions

FDA Approves Expanded Indications for 2 HIV TherapiesSeptember 25, 2019 14:27
Merck’s Pifeltro (Doravirine) and Delstrigo (doravirine/lamivudine/tenofovir Disoproxil Fumarate) Receive FDA Approval for Use in Appropriate Adults Living with HIV-1 Who Are Virologically SuppressedSeptember 24, 2019 04:51
Merck Announces Presentation of Phase 2b Results for Investigational HIV-1 Therapy Islatravir (MK-8591) at IAS 2019July 24, 2019 22:55
Join now to see all

Grant Support

Selection Of Multidrug Resistant Hiv-1rtNational Institute Of Allergy And Infectious Diseases2001
Selection Of Multidrug Resistant Hiv-1rtNational Institute Of Allergy And Infectious Diseases1999–2001